AstraZeneca faces growing pushback on drug prices and the looming loss of exclusivity on some of its biggest medicines, which could make it harder to keep profits rising. The key question is whether new launches and global growth can offset these headwinds, or if the business slows as competition and regulation bite.Read more

Rooftop solar, home batteries, and shifting rules in California could slowly chip away at Edison International’s customer demand while wildfire liabilities and rising costs keep pressure on profits. See why some analysts think the company may struggle to earn enough on big grid upgrades unless regulators consistently let it recover those costs.Read more